Satralizumab
- Generic Name
- Satralizumab
- Brand Names
- Enspryng
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1535963-91-7
- Unique Ingredient Identifier
- YB18NF020M
- Background
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the cent...
- Indication
Satralizumab is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. In Canada, it is also used in adolescent patients for the same indication.
- Associated Conditions
- Neuromyelitis Optica Spectrum Disorders
- Associated Therapies
- -
Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
- Conditions
- Interventions
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 85
- Registration Number
- NCT02028884
- Locations
- 🇫🇷
Hopital de Hautepierre CHRU de Strasbourg, Strasbourg, France
🇩🇪NeuroCure Clinical Research Center (NCRC), Berlin, Germany
🇵🇱M.A. - LEK A. M. Maciejowscy SC. Centrum Terapii SM, Katowice, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.